Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Non-myeloablative allogeneic hematopoietic stem cell transplantation
- Development stage
- Unknown
- Lead developer
- Richard Burt
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
Non-myeloablative allogeneic hematopoietic stem cell transplantation (HSCT) is an experimental cellular therapy protocol developed by Richard Burt, MD, at Northwestern University for the treatment of primary biliary cholangitis (PBC). The procedure involves a conditioning regimen consisting of cyclophosphamide, fludarabine, and alemtuzumab (CAMPATH-1H) to suppress the patient's existing immune system, which is responsible for destroying the bile ducts. Following conditioning, hematopoietic stem cells from an HLA-matched sibling are infused to reconstitute a healthy immune system that does not attack the liver tissue. This approach aims to stop or reverse disease progression in patients who have failed standard therapies like ursodeoxycholic acid.
- Other names
- Allogeneic HSCT for Primary Biliary CirrhosisNon-myeloablative HSCT
Beyond the preview
Go deeper on Non-myeloablative allogeneic hematopoietic stem cell transplantation.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Non-myeloablative allogeneic hematopoietic stem cell transplantation.